Secondary data use of tocilizumab clinical studies to address regulatory needs for rare and pediatric trials

Innovative designs, extrapolation, simulation methods and evidence - tools for rare diseases addressing regulatory needs (INVENTS project) - secondary data use of tocilizumab clinical studies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13592648

Enrollment

111530

Registered

2026-01-16

Start date

2005-01-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic/polyarticular juvenile idiopathic arthritis, giant cell arteritis and rheumatoid arthritis Musculoskeletal Diseases

Interventions

The methods that will be developed during this study will enable the exploitation of novel and improved clinical trial designs, in silico trials and real-world data (including real-world data from pat

Eligibility

Sex/Gender

All

Age

1 Days to 100 Years

Inclusion criteria

Inclusion criteria: All patients included in the 20 clinical studies.

Exclusion criteria

Exclusion criteria: GDPR non compliant countries

Countries

Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Scotland, Singapore, Slovakia, Spain, Sweden, Switzerland, Thailand, United States of America

Contacts

Public ContactSarah;David Zohar;Pau

;

sarah.zohar@inserm.fr;david.pau@roche.com+33 01 44 27 92 03;+33 0673995067

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026